Wei Li

High Impact

Assistant Professor

UAMS

Also affiliated: Wannan Medical College (2012); Qingdao University (2013–2023); Union Hospital (2018); Shanghai Medical College of Fudan University (2013); Central South University (2013–2017); Army Medical University (2025); Bristol-Myers Squibb (Germany) (2016); Guangxi Medical University (2019–2023); National University of Defense Technology (2024); Henan University (2022); Guangdong Medical College (2018); University of Dundee (2009–2012); Pfizer (United States) (2018–2025); Shanghai Jiao Tong University (2016–2019); Capital Medical University (2011–2025); Xiamen University (2018); Dalian Medical University (2025); Jilin University (2014–2022); Chengdu Medical College (2021); Sichuan University (1999–2025); Beijing Chao-Yang Hospital, Capital Medical University (2015–2016); Liaoning University of Traditional Chinese Medicine (2021); Ninewells Hospital (2005–2012); Harefield Hospital (2023–2025); Southwest Medical University (2024); Zhengzhou University (2018–2022); Affiliated Hospital of Southwest Medical University (2024); Endocrinology Research Center (2009); First Affiliated Hospital of Xiamen University (2019); Third Affiliated Hospital of Southern Medical University (2017); West China Second University Hospital of Sichuan University (2018); West China Hospital of Sichuan University (2007–2025); Center For Children With Special Needs (2011); Bristol-Myers Squibb (United States) (2016); Daping Hospital (2025); Longgang Central Hospital (2023); Ministry of Education (2013); Shanghai Ninth People's Hospital (2016); Second Affiliated Hospital of Chongqing Medical University (2025); Fourth People’s Hospital of Jinan (2023); Jinshan Hospital of Fudan University (2013); Center for Children (2024); ShenZhen People’s Hospital (2023); First People's Hospital of Foshan (2019); Taizhou Fourth People's Hospital (2025); National Center for Women and Children’s Health, China CDC (2022); Wuhan No.1 Hospital (2024); Tianjin Children's Hospital (2016); Guangzhou First People's Hospital (2025); Affiliated Hospital of Qingdao University (2013); Beijing Anzhen Hospital (2025); Zero to Three (2019); Hangzhou Academy of Agricultural Sciences (2016); First Hospital of Jilin University (2014–2022); First Affiliated Hospital of GuangXi Medical University (2019–2023); Guangzhou Institute of Dermatology (2023); The First People’s Hospital of Lianyungang (2025); The Affiliated Yongchuan Hospital of Chongqing Medical University (2025); People's Hospital of Shiyan (2025); Henan Provincial People's Hospital (2017–2022); Tibet Autonomous Region People's Hospital (2021); Wuhan National Laboratory for Optoelectronics (2024); SwissLitho (Switzerland) (2016); Second Affiliated Hospital of Jilin University (2024); Henan Cancer Hospital (2018); Beijing Children’s Hospital (2019–2024); Shanghai Sixth People's Hospital (2017–2019); Affiliated Hospital of Guilin Medical College (2024); Beijing Hospital of Traditional Chinese Medicine (2019); Beijing Chuiyangliu Hospital (2015–2016); Beijing Tsinghua Chang Gung Hospital (2024); Nanjing Jiangning Hospital (2025); First Affiliated Hospital of Zhengzhou University (2025); Nanchong Central Hospital (2023); Affiliated Hospital of Guangdong Medical College Hospital (2018); Xiangya Hospital Central South University (2017); Qilu Hospital of Shandong University (2012); First People's Hospital of Chongqing (2011); Jinan City People's Hospital (2020–2023); Shandong First Medical University (2020–2023); Union Hospital (2018); Sichuan Center for Disease Control and Prevention (2014); State Key Laboratory of Oral Diseases (2010–2017); Shanghai Ocean University (2025); Huazhong University of Science and Technology (2024); Indiana University (2018); Chongqing Medical University (2025); South China University of Technology (2025); Guangzhou Medical University (2023–2025); Zhongkai University of Agriculture and Engineering (2022)

Faculty Researcher

CHP | Dietetic Internship

27 h-index 233 pubs 3,286 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 91 institutions in 7 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID UAMS TRI Profile

OverviewAI-generated summary

Wei Li's research focuses on dermatological conditions, particularly psoriasis and bullous pemphigoid. Li has investigated the therapeutic applications of various treatments, including Dupilumab for bullous pemphigoid and Janus kinase inhibitors like Baricitinib for concurrent bullous pemphigoid and plaque psoriasis. Their work also explores the underlying mechanisms of these diseases, such as the role of IL-17A in cancer treatment and the contribution of SerpinB7 deficiency to psoriasis development through calcium-mediated keratinocyte differentiation dysfunction.

Further investigations include the application of single-cell RNA sequencing in understanding atopic dermatitis and psoriasis, and the potential of gut microbiota alterations, specifically the presence of *Eubacterium rectale*, as a marker in psoriasis and psoriatic arthritis. Li's research extends to nutritional status in cancer patients, with a study establishing reference values for low body mass index, mid-upper arm circumference, and calf circumference. With an h-index of 27 and over 3,200 citations across more than 230 publications, Li is recognized as a highly cited researcher.